Enlivex Therapeutics Ltd. (ENLV)
1.01
0.00 (0.00%)
At close: Mar 28, 2025, 3:59 PM
1.00
-0.83%
After-hours: Mar 28, 2025, 07:57 PM EDT
Enlivex Therapeutics Ltd. Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | n/a | n/a | n/a | 2.28M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 835K | 777K | 546K | 286K | 297K | 121K | 12K | 25K | 17K | n/a | n/a | n/a |
| Gross Profit | -835K | -777K | -546K | 1.99M | -297K | -121K | -12K | -25K | -17K | n/a | n/a | n/a |
| Operating Income | -29.39M | -25.8M | -19.29M | -9.79M | -8.62M | -5.3M | -5.96M | -15.87M | -15.48M | -7.08M | -1.15M | -226K |
| Interest Income | 1.56M | 835K | 120K | 225K | 238K | 138K | 39K | 90K | 186K | 85K | n/a | n/a |
| Pretax Income | -29.07M | -31.06M | -14.47M | -11.82M | -9.38M | -4.24M | -5.92M | -15.81M | -15.34M | -7.02M | -1.15M | -229K |
| Net Income | -29.07M | -42.41M | -9.65M | -13.86M | -10.15M | -4.24M | -5.95M | -16.02M | -15.37M | -7.02M | -1.15M | -229K |
| Selling & General & Admin | 6.14M | 6.7M | 6.24M | 3.6M | 2.75M | 937K | 3.44M | 6.99M | 7.78M | 2.64M | 416K | 86K |
| Research & Development | 19.23M | 18.69M | 12.88M | 6.09M | 5.72M | 4.25M | 2.52M | 8.88M | 7.69M | 4.44M | 732K | 140K |
| Other Expenses | 4.02M | 402K | 167K | 97K | 145K | n/a | n/a | n/a | -829K | n/a | n/a | n/a |
| Operating Expenses | 29.39M | 25.8M | 19.29M | 9.79M | 8.62M | 5.3M | 5.96M | 15.87M | 15.48M | 7.08M | 1.15M | 226K |
| Interest Expense | 14K | 5.26M | 328K | 6K | 7K | n/a | n/a | n/a | n/a | n/a | 2K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 479K | n/a | 829K | n/a | n/a | n/a |
| Cost & Expenses | 29.39M | 25.8M | 19.29M | 9.79M | 8.62M | 5.3M | 5.96M | 15.87M | 15.48M | 7.08M | 1.15M | 226K |
| Income Tax | n/a | 11.35M | -4.82M | 2.04M | 765K | 1.06M | 28K | 216K | 24K | n/a | 2K | n/a |
| Shares Outstanding (Basic) | 18.57M | 18.39M | 17.86M | 13.17M | 8.65M | 3.51M | 414.2K | 397.65K | 355.76K | 306.49K | 271.85K | 271.85K |
| Shares Outstanding (Diluted) | 18.57M | 18.39M | 17.86M | 13.17M | 8.65M | 3.51M | 428.24K | 397.65K | 355.76K | 306.49K | 271.85K | 271.85K |
| EPS (Basic) | -1.56 | -2.31 | -0.54 | -1.05 | -1.17 | -1.21 | -14.35 | -40.29 | -43.19 | -22.91 | -4.21 | -0.84 |
| EPS (Diluted) | -1.56 | -2.31 | -0.54 | -1.05 | -1.17 | -1.21 | -13.88 | -40.29 | -43.19 | -22.91 | -4.21 | -0.84 |
| EBITDA | -28.22M | -25.02M | -18.74M | -9.5M | -9.08M | -5.18M | -5.91M | -15.78M | -15.31M | -7.08M | -1.14M | -226K |
| Depreciation & Amortization | 835K | 777K | 546K | 286K | 297K | 121K | 12K | 25K | 17K | 5K | 5K | n/a |